jetcityimage/iStock editorial via Getty Images
human (New York Stock Exchange: HUM) shares trade slightly lower before trading on Wednesday despite fourth-quarter results beating estimates.
Fourth quarter adjusted EPS increased +30.6% yoy to $1.62, while revenue increased +6.6% yoy to $22.44bn. Both the top and bottom results exceeded analysts’ expectations.
The benefits expense ratio was 87.3%, compared to 87.9% in the fourth quarter of 2021.
Whole year Income 2022 grew +11.8% Y/Y to $92.87B. The benefit expense ratio was 86.3%, compared to 86.7% in 2021.
“Humana is pleased to start the year in a strong position, with strong Medicare Advantage (MA) individual membership growth by 2023 expected to be at least 625,000 for the year, up 13.7 percent year-over-year. “said the president of Humana. and CEO Bruce Broussard.
During December 2022, Humana realigned sure of your business among its previously reportable segments, Retail, Group and Specialty and Healthcare Services, into two distinct segments: Insurance and CenterWell.
income from insurance segment grew +7.2% Y/Y to $21.60 in Q4. The expense to profit ratio was 87.5%, compared to 88.5% in the fourth quarter of 2021.
CenterWell Segment revenue increased +1.4% Y/Y to $4.14B.
panorama 2023:
Humana expects an adjusted EPS of at least $28 (consensus $28.01).
The company expects GAAP EPS to be at least $27.57. GAAP EPS for full year 2022 was $22.08.
“Looking forward, we are confident of achieving our adjusted EPS commitment of $37 by 2025,” Broussard added. The consensus for 2025 is $37.13.
HUM -0.39% at $509.69 before marketing on February 1
